The Overweight rating by Cantor Fitzgerald suggests that they expect Denali Therapeutics' stock to outperform in the market. However, the lowering of the price target might indicate a tempered expectation of the stock's future performance. This could lead to mixed reactions in the market, but overall, the positive rating is likely to have a positive impact on the stock's price in the short term.